Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion

LIPELLA PHARMACEUTICALS INC.

Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.
Net proceeds of $602,580; Spartan Capital received $123,420 in fees, 84,700 Series C voting preferred shares and warrants for 28,924 common shares.
CEO Jonathan Kaufman granted irrevocable voting power over Spartan's issued shares via proxy.
Proceeds from the offering to be used for working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.